Back to results
US 2022/0054497 A1Published application
PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS
AssigneeAdams Pharmaceuticals LLC
InventorsJonathan Adams, Peter Jeffrey Adams
Life of this patent
Estimating the term…
Abstract
The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
Claims1
A method of reducing the likelihood of developing atherosclerosis in a human, comprising:
- measuring factor Xa activity in a patient, and
- administering an inhibitor of factor Xa in an amount effective to reduce activity of factor Xa by 25% or more in a patient having a measured normal factor Xa activity.
Dependencies are inferred from the claim text.